Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 20;13(3):189.
doi: 10.3390/pathogens13030189.

New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides

Valentina Siciliano  1 , Flavio Sangiorgi  2 , Pierluigi Del Vecchio  2 , Layla Vahedi  2 , Maya Manuela Gross  2 , Angela Saviano  3 , Veronica Ojetti  3
Affiliations
Review

New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides

Valentina Siciliano et al. Pathogens. .

Abstract

Long-acting lipoglycopeptides (LGPs), such as dalbavancin and oritavancin, are semisynthetic antibiotics known for their strong effectiveness against a wide array of Gram-positive bacteria. This includes Staphylococcus aureus, both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains, coagulase-negative Staphylococci (CoNS), streptococci, and vancomycin-sensitive Enterococcus faecalis. A literature search was conducted on PubMed and on ClinicalTrials.gov to identify articles published until July 2023 investigating the use of oritavancin and dalbavancin in clinical practice. The review included case reports, case series, observational studies, and clinical studies. Although more consistent data are needed, LGPs seem to be a good alternative that may provide a quicker hospital discharge and reduce long-term intravenous access and therapy. This is attributed to their unique pharmacologic and pharmacokinetic characteristics. More quality data (i.e., number of patients treated with clinical success) are needed before clinicians may use these therapies more widely.

Keywords: dalbavancin; long-acting lipoglycopeptides; oritavancin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Roecker A.M., Pope S.D. Dalbavancin: A lipoglycopeptide antibacterial for Gram-positive infections. Expert Opin. Pharmacother. 2008;9:1745–1754. doi: 10.1517/14656566.9.10.1745. - DOI - PubMed
    1. Brade K.D., Rybak J.M., Rybak M.J. Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections. Infect. Dis. Ther. 2016;5:1–15. doi: 10.1007/s40121-016-0103-4. - DOI - PMC - PubMed
    1. Zeng D., Debabov D., Hartsell T.L., Cano R.J., Adams S., Schuyler J.A., McMillan R., Pace J.L. Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance. Cold Spring Harb. Perspect. Med. 2016;6:a026989. doi: 10.1101/cshperspect.a026989. - DOI - PMC - PubMed
    1. Kim S.J., Cegelski L., Stueber D., Singh M., Dietrich E., Tanaka K.S., Parr T.R., Far A.R., Schaefer J. Oritavancin Exhibits Dual Mode of Action to Inhibit Cell-Wall Biosynthesis in Staphylococcus aureus. J. Mol. Biol. 2008;377:281–293. doi: 10.1016/j.jmb.2008.01.031. - DOI - PMC - PubMed
    1. Barberán J.A., Cuerda D.L., Barberán L.C. Dalbavancin. Rev. Esp. Quimioter. 2021;34:26–28. doi: 10.37201/req/s01.07.2021. - DOI - PMC - PubMed

MeSH terms